Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

BACKGROUND. The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. Bevacizumab-treated patients may show pseudo-response on postcontrast T1-weighted (T1w) MRI, and a more infiltrative non-enhancing growth p...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Gahrmann, Renske, van den Bent, Martin, van der Holt, Bronno, Vernhout, René Michel, Taal, Walter, Vos, Maaike, de Groot, Jan Cees, Beerepoot, Laurens Victor, Buter, Jan, Flach, Zwenneke Hendrieke, Hanse, Monique, Jasperse, Bas, Smits, Marion
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Clinical Investigations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464446/
https://ncbi.nlm.nih.gov/pubmed/28204639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now311
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki